Scienture (NASDAQ:SCNX) Posts Quarterly Earnings Results, Beats Estimates By $0.15 EPS

Scienture (NASDAQ:SCNX) posted its earnings results on Friday. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.15, FiscalAI reports. The business had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.40 million.

Scienture Stock Performance

Scienture stock traded down $0.01 during trading hours on Friday, hitting $0.40. 202,409 shares of the stock were exchanged, compared to its average volume of 2,380,695. The stock has a market capitalization of $16.37 million, a P/E ratio of -0.15 and a beta of 3.32. Scienture has a 12 month low of $0.24 and a 12 month high of $2.60. The business’s 50-day moving average is $0.40 and its two-hundred day moving average is $0.50.

Institutional Trading of Scienture

A hedge fund recently raised its stake in Scienture stock. Geode Capital Management LLC grew its position in shares of Scienture Holdings, Inc. (NASDAQ:SCNX) by 264.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 316,201 shares of the company’s stock after buying an additional 229,398 shares during the quarter. Geode Capital Management LLC owned approximately 0.78% of Scienture worth $161,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 5.68% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Maxim Group assumed coverage on shares of Scienture in a research note on Tuesday, February 24th. They issued a “buy” rating and a $1.50 target price on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Scienture in a research note on Friday, March 27th. Finally, Wall Street Zen raised shares of Scienture to a “hold” rating in a research note on Saturday, March 14th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $1.50.

About Scienture

Scienture Holdings, Inc engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.